This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
The average time of dilation lasts three to eight hours
This acquisition enables MTD to open new, strategic markets
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Executes the first project for developing and manufacturing a novel anticancer mAb
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Subscribe To Our Newsletter & Stay Updated
